Search clinical trials for: Generic Budesonide/Formoterol Fumarate Dihydrate

Total 490 results

AstraZeneca

Completed

STYLE - Symbicort Single Inhaler Therapy vs Conventional Therapy in Treatment of Persistent Asthma

Asthma

Croatia, Czech Republic, Latvia, Lithuania, Portugal, Slovakia, Greece, Iceland, Slovenia, Chile
AstraZeneca

Active, not recruiting

Outcomes in Real-life After Initation of Treatment With Trixeo (Budesonide / Glycopyrronium / Formoterol) (CHOROS ORION)

Chronic Obstructive Pulmonary Disease

Italy
AstraZeneca

Completed

A Comparison of the Control of Asthma Provided by Symbicort® Turbuhaler® Versus Symbicort® Turbuhaler® Plus Pulmicort® Turbuhaler® Plus Terbutaline Turbuhaler®

Asthma

Sweden, France, United Kingdom, Germany, Denmark, Spain
Fasa University of Medical Sciences

Unknown

Evaluation of Efficacy of Levamisole and Formoterol+Budesonide in Treatment of COVID-19

COVID-19

Iran, Islamic Republic of
Zhujiang Hospital

Unknown

Differences of Small Airways Function Between Chronic Obstructive Pulmonary Disease(COPD) and Asthma-copd Overlap(ACO)

Quality of Life | Pulmonary Disease, Chronic Obstructive | Asthma-Chronic Obstructive Pulmonary Disease Overlap Syndrome | Small Airway Disease

China
Zhujiang Hospital

Unknown

Change of Lung Function After Exercise in Patients With Chronic Obstructive Pulmonary Disease

Quality of Life | Pulmonary Disease, Chronic Obstructive | Exercise | Lung Function Decreased

China
Zhujiang Hospital

Unknown

Small Airways Evaluation and Treatment

Pulmonary Disease，Chronic Obstructive;

China
SkyePharma AG

Completed

New Combination Inhaler (FlutiForm HFA MDI 100/10 µg and 250/10 µg) Versus Fluticasone and Formoterol Administered Alone, and Placebo in Patients With Moderate to Severe Asthma

Asthma

United States, Puerto Rico
AstraZeneca

Active, not recruiting

Real-world, 52-week Prospective Study to Capture the Reasons for Switch to Triple Combination Therapy, Assess the Clinical and Patient Reported Outcomes in Adults With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) Treated With Trixeo Aerosphere™ in Routine Care Settings in Greece (TRIAENA)

Pulmonary Disease, Chronic Obstructive (COPD)

Greece
Pearl Therapeutics, Inc.

Completed

A Study to Assess the PK and Safety of PT010 in Subjects With COPD Following Single and Repeat Dose

Chronic Obstructive Pulmonary Disease

United States
University of KwaZulu

Not yet recruiting

Anti-Inflammatory Reliever South Africa (AIRSA001)

Asthma
AstraZeneca

Completed

Comparing Symbicort® As-Needed or Bricanyl As-Needed or Pulmicort® Once Daily + Bricanyl As-Needed in Asthma Patients (MIA)

Exercise Induced Asthma

Sweden, Norway
Gelb, Arthur F., M.D.

Recruiting

Mechanism(s) of Airflow Limitation During Exacerbation of Asthma

Asthma

United States
Peking University People's Hospital
First Affiliated Hospital of Liaoning University of Traditional Chinese Medicine

Unknown

Yiqi Huoxue Huatan Granule for Reducing Mortality in COPD With Chronic Respiratory Failure

Chronic Obstructive Pulmonary Disease | Chronic Respiratory Failure

China
Sunovion

Completed

Study of Arformoterol Tartrate Inhalation Solution and Racemic Formoterol in Subjects With Mild to Moderate Chronic Obstructive Pulmonary Disease (COPD)

COPD

United States
UCSF Benioff Children's Hospital Oakland
National Cancer Institute (NCI)

Completed

Topical Tazarotene in Treating Patients With Basal Cell Skin Cancer and Basal Cell Nevus Syndrome on the Chest and Back

Skin Carcinoma

United States
Maisonneuve-Rosemont Hospital
The Canadian Blood and Marrow Transplant Group

Terminated

Steroids, Azithromycin, Montelukast, and Symbicort (SAMS) for Viral Respiratory Tract Infection Post Allotransplant

Respiratory Tract Infections | Lung Diseases, Interstitial | Bronchiolitis Obliterans | Cryptogenic Organizing Pneumonia

Canada
Pearl Therapeutics, Inc.

Completed

Pharmacokinetics and Safety Study of PT010 and PT003 in Healthy Chinese Adult Subjects

Chronic Obstructive Pulmonary Disease

China
AstraZeneca

Completed

Efficacy and Safety Study to Compare Formoterol Fumerate in the Pressair DPI to the Foradil Aerolizer in Patient With Mild to Moderate Asthma

Asthma

United States
Pearl Therapeutics, Inc.

Completed

Study to Assess the Safety and Efficacy of PT010, PT003, and PT009 in Japanese Subjects With COPD Compared With Symbicort® Turbohaler®

COPD

Japan
Sunovion

Completed

To Evaluate the Long-term Safety of (R,R)-Formoterol in Subjects With COPD

Chronic Obstructive Pulmonary Disease | Emphysema | Chronic Bronchitis

United States
University of Alberta

Recruiting

Cardiovascular Consequences of Inhaled Short-acting Beta-agonist Use

Healthy

Canada
Novartis
Schering-Plough

Completed

Single Dose Study of the Effect of Formoterol Fumarate in Combination With Mometasone Furoate Inhaled Via a Pressurized Metered Dose Inhaler (pMDI) in Children Aged 5-11 Years Old With Persistent Asthma

Asthma

United States, Colombia, Peru
GlaxoSmithKline

Completed

CONCEPT: A 1-Year Comparison Of A Stable Dose Of SERETIDE® Inhaler With An Adjustable Maintenance Dose Of SYMBICORT® Inhaler. SERETIDE® Inhaler is a Trademark of GSK Group of Companies. SYMBICORT® Inhaler is a Trademark of Astra Zeneca.

Asthma

Canada, Bulgaria, Estonia, Spain, Netherlands, Germany, Australia, Austria, Belgium, Finland, Ireland, Latvia, Macedonia, The Former Yugoslav Republic of, New Zealand, United Kingdom
Orion Corporation, Orion Pharma

Completed

Pharmacokinetic Pilot Study on Budesonide/Formoterol Device-metered Dry Powder Inhalers (Reco-Pilot)

Asthma

Finland
AstraZeneca

Completed

Comparison Between Symbicort® and Prednisolone in COPD (SPACE)

Chronic Obstructive Pulmonary Disease

Sweden, Germany, Norway, Denmark, Finland
Intech Biopharm Ltd.

Completed

A Bioequivalence Pivotal Study of SYN010 HFA Inhaler and Symbicort® 160/4.5 in Healthy Volunteers With Charcoal Block

Asthma | Chronic Obstructive Pulmonary Disease (COPD)
SkyePharma AG

Completed

Comparison of New Combination Inhaler (FlutiForm HFA MDI 100/10 µg) Versus Fluticasone & Formoterol Administered Alone in Patients With Asthma

Asthma

United States, Canada
Dey

Completed

A Study Evaluating Systemic Exposure and Pharmacodynamics in Patients With Chronic Obstructive Pulmonary Disease

Chronic Obstructive Pulmonary Disease

United States
AstraZeneca

Recruiting

Change in Patient-repOrted Outcomes in COPD Patients Newly Initiated on TRIXEO AEROSPHERE in Real worlD (COnCORD)

Chronic Obstructive Pulmonary Disease (COPD)

Romania
Washington University School of Medicine
National Institutes of Health (NIH); National Center for Advancing Translational...

Recruiting

Symptom-driven ICS/LABA Therapy for Patients With Asthma Non-adherent to Daily Maintenance Inhalers

Asthma | Nonadherence, Medication

United States
Chiesi Farmaceutici S.p.A.

Completed

Foster® pMDI (CHF 1535) Versus Symbicort® Turbohaler in COPD Patient (FORSYYN)

Chronic Obstructive Pulmonary Disease

China
Pearl Therapeutics, Inc.

Completed

24-hour Lung Function in Subjects With Moderate to Very Severe COPD After Treatment With PT003 and Placebo MDI

COPD
AstraZeneca
Iqvia Pty Ltd; Premier Inc.

Withdrawn

IKANOS: Breztri Maintenance Versus Any Non-Triple Inhaled Therapy After Hospitalization for a COPD Exacerbation in the US (IKANOS)

COPD

United States
Intech Biopharm Ltd.

Completed

A Bioequivalence Pivotal Study of SYN010 HFA Inhaler and Symbicort® 160/4.5 in Healthy Volunteers Without Charcoal Block

Asthma | COPD

Taiwan
Washington University School of Medicine
National Institutes of Health (NIH); National Center for Advancing Translational...

Recruiting

Symptom-driven ICS/LABA Therapy for Adolescent Patients With Asthma Non-adherent to Daily Maintenance Inhalers

Asthma in Children | Nonadherence, Medication

United States
Neutec Ar-Ge San ve Tic A.Ş

Completed

Assessment of Bronchodilator Efficacy of Formoterol/Budesonide 12/400 mcg Via Discair in COPD (COPD)

Copd

Turkey
University of British Columbia
AstraZeneca

Unknown

A Study to Investigate the Differential Effects of Inhaled Symbicort and Advair on Lung Microbiota (DISARM)

Chronic Obstructive Pulmonary Disease

Canada
AstraZeneca

Completed

Airway Clearance Study

Chronic Obstructive Pulmonary Disease

United Kingdom, Sweden
Sanofi
Regeneron Pharmaceuticals

Completed

Evaluation of Dupilumab's Effects on Airway Inflammation in Patients With Asthma (EXPEDITION)

Asthma

Denmark, United States, Canada, Germany, Sweden, United Kingdom
National Jewish Health

Completed

Sub-Sensitivity to Long-Acting Bronchodilators (LABA)

Asthma

United States
AstraZeneca

Completed

SOLO-Symbicort® in the Treatment of Persistent Asthma in Adolescents & Adults

Asthma

Canada
Organon and Co

Completed

Study of Mometasone Furoate/Formoterol Fumarate (MF/F) Metered Dose Inhaler (MDI) in Adolescents & Adults With Persistent Asthma (P08212)

Asthma
Pearl Therapeutics, Inc.

Completed

Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD

Chronic Obstructive Pulmonary Disease

United States, Germany, United Kingdom, China, Taiwan, Korea, Republic of, Japan, Czechia, Hungary, Poland, Russian Federation
University of Dundee
AstraZeneca; NHS Tayside

Completed

Microbiome Use to Stratify Use of Inhaled Corticosteroids: MUSIC Trial (MUSIC)

Chronic Obstructive Pulmonary Disease

United Kingdom
SkyePharma AG

Completed

Comparison of New Combination Inhaler (FlutiForm HFA MDI 100/10 µg) Versus Fluticasone and Formoterol Administered Alone, and Placebo, in Patients With Asthma

Asthma

United States, Canada
Brigham and Women's Hospital

Completed

Replication of the P04334 Asthma Trial in Healthcare Claims Data

Asthma

United States
Sunovion

Completed

A Pivotal Study of the Safety and Effectiveness of Arformoterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

COPD

United States
AstraZeneca

Recruiting

Study to Assess PT010 in Adult and Adolescent Participants With Inadequately Controlled Asthma (LOGOS) (LOGOS)

Asthma

United States, China, Czechia, Germany, South Africa, United Kingdom, Mexico, Turkey, Colombia, Russian Federation, Brazil, Israel, Greece, Portugal, Austria, Costa Rica, Saudi Arabia, Slovakia, Sweden, Puerto Rico
Pearl Therapeutics, Inc.

Completed

Phase I Study Evaluating the Safety and Pharmacokinetics of Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol (BGF MDI) in Healthy Volunteers

Healthy Volunteers

United States

3

Subscribe